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Background. The effects of antiretrovirals on cystatin C-based renal function estimates are unknown.
Methods. We analyzed changes in renal function using creatinine and cystatin C-based estimating equations in
269 patients in A5224s, a substudy of study A5202, in which treatment-naive patients were randomized to abacavir/
lamivudine or tenofovir/emtricitabine with open-label atazanavir/ritonavir or efavirenz.
Results. Changes in renal function signiﬁcantly improved (or declined less) with abacavir/lamivudine treatment
compared with tenofovir/emtricitabine using the Cockcroft-Gault formula (P = .016) and 2009 Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI; P = .030) and 2012 CKD-EPI cystatin C-creatinine (P = .025). Renal
function changes signiﬁcantly improved (or declined less) with efavirenz compared with atazanavir/ritonavir
(P < .001 for all equations). Mean (95% conﬁdence interval) renal function changes speciﬁcally for tenofovir/emtri-
citabine combined with atazanavir/ritonavir were −8.3 (−14.0, −2.6) mL/min with Cockcroft-Gault; −14.9 (−19.7,
−10.1) mL/min per 1.732 with Modiﬁcation of Diet in Renal Disease; −12.8 (−16.5, −9.0) mL/min per 1.732 with
2009 CKD-EPI; +8.9 (4.2, 13.7) mL/min per 1.732 with 2012 CKD-EPI cystatin C; and −1.2 (−5.1, 2.6) mL/min per
1.732 with 2012 CKD-EPI cystatin C-creatinine. Renal function changes for the other treatment arms were more
favorable but similarly varied by estimating equation.
Conclusions. Antiretroviral-associated changes in renal function vary in magnitude and direction based on the
estimating equation used.
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Antiretroviral therapy (ART) may negatively affect renal
function through drug toxicity mechanisms [1] or im-
prove renal function by ameliorating the detrimental ef-
fects of untreated human immunodeﬁciency virus (HIV)
on the kidney [2, 3]. Several studies have suggested that
use of tenofovir disoproxil fumarate is associated with
worse changes in estimated glomerular ﬁltration rate
(eGFR) compared with other nucleoside reverse-
transcriptase inhibitors (NRTIs), and that this effect is
magniﬁed with concomitant use of protease inhibitors
(PIs) [4–8]. However, not all studies have conﬁrmed this
relationship [9–11]. In the AIDS Clinical Trials Group
(ACTG) 5202 trial, worse changes in eGFR (estimated as
creatinine clearance using the Cockcroft-Gault equation
[12]) were found with the use of tenofovir/emtricitabine
compared with abacavir/lamivudine, especially when te-
nofovir/emtricitabine was used in combination with ata-
zanavir/ritonavir [13]. Other observational studies have
suggested that the antiretroviral PI combination atazana-
vir/ritonavir also negatively affects renal function [14, 15].
There is growing interest in the use of serum cystatin C
as a new marker of renal function. Compared with serum
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creatinine, cystatin C is not affected by muscle mass and is
completely eliminated by the kidney through glomerular ﬁltration.
Perhaps because of this improved ability to measure glomerular
ﬁltration, cystatin C seems to have greater utility over creatinine
in predicting adverse outcomes in both the general population
[16–18] and in the HIV-infected population [19, 20]. As such,
newer GFR-estimating equations have been developed using cys-
tatin C, including the 2012 Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) cystatin C equation, which uses cystatin
C only without creatinine, and the 2012 CKD-EPI cystatin
C-creatinine equation, which incorporates both markers [21]. In
the general US population [18], identifying renal dysfunction with
the 2012 CKD-EPI cystatin C-creatinine combined equation ap-
pears to be more predictive of cardiovascular disease, end stage
renal disease, and overall mortality compared with the 2012
CKD-EPI cystatin C equation and the older 2009 CKD-EPI equa-
tion [22], the latter of which includes only serum creatinine. A re-
cent study in women infected with HIV suggested that both of the
newer 2012 cystatin C-based equations were more accurate than
the 2009 CKD-EPI equation in identifying those patients with
renal dysfunction with greater risk of mortality [20].
A recent American study using iohexol clearance as the refer-
ence measurement of GFR assessed the accuracy of these newer
cystatin C-based equations in patients infected with HIV, most of
whom were receiving antiretroviral medications, and found that
that the 2012 CKD-EPI cystatin C-creatinine combined equation
most accurately estimated GFR compared with the 2012 CKD-
EPI cystatin C equation and the original 2009 CKD-EPI equation
[23]. Another American study corroborated these ﬁndings by
again ﬁnding that the 2012 CKD-EPI cystatin C-creatinine com-
bined equation was more accurate than the other 2 CKD-EPI
equations when compared with direct GFR measurement using
iohexol clearance [24]. However, in a similar study conducted
in Europe, no appreciable differences were found between the
combined 2012 CKD-EPI equation and the 2009 CKD-EPI equa-
tion [25]. Of note, both of these HIV studies suggest that all 3
CKD-EPI equations were signiﬁcantly more accurate than the
Modiﬁcation of Diet in Renal Disease (MDRD) equation [22],
which is important given that much of our understanding of
the effects of antiretrovirals on renal function from observational
cohort studies used this latter equation [7, 26].
Therefore, we assessed changes in renal function using 5 dif-
ferent estimating equations in ACTG 5224s, a substudy of
ACTG 5202, in which cystatin C was systematically measured,
and assessed the nephrotoxicity proﬁles with commonly used
once-daily regimens.
METHODS
Study Design and Procedures
The ACTG A5224s was a metabolic substudy of A5202 (Clinical
Trials.gov NCT00118898) in which ART-naive study parti-
cipants from ACTG sites in the United States and Puerto
Rico aged ≥16 years and with an HIV-1 RNA level >1000
copies/mL were randomized to a blinded NRTI component,
abacavir/lamivudine or tenofovir/emtricitabine, with either
the open-label PI atazanavir/ritonavir or the non-NRTI
(NNRTI) efavirenz. A secondary objective of A5224s was to
compare the effects of initiating abacavir/lamivudine with
those of tenofovir/emtricitabine on renal function after 96
weeks. A secondary renal objective was to compare the effects
of atazanavir/ritonavir with efavirenz on these endpoints after
96 weeks. As previously described [27], the NRTI assignment
was prematurely unblinded for patients with A5202 screening
HIV-1 RNA at least 100 000 copies/mL because of higher
rates of virologic failure with abacavir/lamivudine regimens.
Renal function was assessed using the following 5 estimating
equations: Cockcroft-Gault, 4-variable MDRD, 2009 CKD-EPI,
2012 CKD-EPI cystatin C, and 2012 CKD-EPI cystatin C-
creatinine. Serum creatinine measurements and urine analyses
for dipstick protein were performed locally at the laboratory of
the participating ACTG site. Serum cystatin C (Siemens N Latex
kit, lower limit of detection 0.05 mg/L, run on the Siemens
Nephelometer II) was measured centrally at Quest Diagnostics.
Neither the serum creatinine nor the serum cystatin C levels
were calibrated against an international standard. These renal
parameters were measured under fasting conditions for at
least 8 hours at study entry (baseline), at week 24, at week 48,
and every 48 weeks afterwards through 96 weeks past the last
A5202 participant enrollment.
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Scienc-
es, and GlaxoSmithKline provided the study medications. The
decision to publish the manuscript was solely that of the academ-
ic authors. All the authors participated in the trial design, data
analysis, and preparation of the manuscript, and all the authors
vouch for the completeness and accuracy of the reported data.
Study Participants
To be included in the parent A5202 trial [27], participants were
required to have a screening creatinine clearance by Cockcroft-
Gault >60 mL/min. The protocol initially did not exclude partic-
ipants with active hepatitis B but was later amended to exclude
participants with a positive hepatitis B surface antigen result
within 6 months of study entry. To be included in A5224s, par-
ticipants also could not have uncontrolled thyroid disease or
American Diabetes Association-deﬁned diabetes mellitus. The
human subjects’ ethics committee at each participating center ap-
proved the study protocol, and written informed consent was ob-
tained from all participants in compliance with the human
experimentation guidelines of the US Department of Health
and Human Services and the Declaration of Helsinki.
Statistical Analysis
The prespeciﬁed secondary study objectives of A5224s were to
compare renal function changes from baseline to week 96
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between pooled and randomized NRTI components (abacavir/
lamivudine vs tenofovir/emtricitabine with third drug com-
bined) and between NNRTI and PI components (atazanavir/
ritonavir vs efavirenz with NRTI combined). All analyses
were performed using intent-to-treat principles based on ran-
domized treatment assignment. All available data and modiﬁca-
tions to randomized treatment were included in these analyses.
For all comparisons, a factorial analysis approach was used, and,
after assessing for treatment effect modiﬁcation by the other
component, theNRTI effectwas assessed by combining efavirenz
and atazanavir/ritonavir arms and vice versa. The P values
below .05 (<.10 for assessing treatment effect modiﬁcation)
were considered statistically signiﬁcant, and nominal values
are reported without adjustment for multiple comparisons.
Analyses were performed using SAS, version 9.2 (SAS Institute
Inc., Cary, NC).
Comparisons of mean changes between regimen components
used 2-sample t tests in the absence of regimen interactions and
adjusted linear regression if interactions existed. Linear regres-
sion, adjusted for NRTI and NNRTI/PI components, was also
used to assess the association of both baseline renal function
stratum (<90 vs ≥90 mL/min for estimated creatinine clearance
or <90 vs ≥90 mL/min per 1.732 for each of the 4 eGFR mea-
sures) and screening HIV-1 RNA level stratum (<100 000 vs
≥100 000 copies/mL) with change in renal function at week
96. To assess baseline factors independently associated with
renal function change, multivariable linear regression models
were constructed initially consisting of factors with univariate
P values <.20 and then, using backwards selection, retained fac-
tors with a P value <.05. The prespeciﬁed baseline factors were
age, sex, race/ethnicity, HIV-1 RNA, CD4 cell count, urine dip-
stick protein (negative vs nonnegative), systolic blood pressure,
diastolic blood pressure, viral hepatitis B or C coinfection, ho-
meostasis model assessment-insulin resistance (using fasting in-
sulin and glucose measures) [28], weight, body mass index, and
total body lean mass from dual-energy x-ray absorptiometry
measurements.
The sample size estimate was based on the primary A5224s
objective of changes in fat distribution [29]. Complete details of
the randomization procedures are described elsewhere [13].
RESULTS
Participant Characteristics
A total of 271 participants from 37 ACTG sites enrolled in
A5224s. Two participants were subsequently found to be ineli-
gible; thus, 269 were included in the analysis population. Enroll-
ment spanned from October 5, 2005 to November 7, 2007. The
disposition of these participants during the trial has been de-
scribed previously. The baseline characteristics of the random-
ized participants are summarized in Table 1. The baseline levels
of renal function using all 5 estimating equations were well
balanced by randomization amongst the 4 arms. However, the
5 renal estimating equations varied for baseline levels of renal
function, with MDRD and 2012 CKD-EPI cystatin C equations
resulting in the lowest renal function estimates and with Cock-
croft-Gault resulting in the highest.
Changes in Renal Function Over Time
The mean (95% conﬁdence interval [CI]) renal function esti-
mates over time using the 5 different estimating equations are
shown in Figure 1. The magnitudes and directions of the change
in eGFR depended on the estimating equation used. For exam-
ple, with the MDRD and the 2009 CKD-EPI equations, renal
function either did not appreciably change or declined with
all treatments. On the other hand, both 2012 cystatin C-based
equations resulted in changes in eGFR that increased or did not
appreciably change with treatment. In general, tenofovir/emtri-
citabine with atazanavir/ritonavir resulted in the worst (least
positive or most negative) changes in eGFR of the 4 treatment
arms at 96 weeks with all 5 equations.
The changes in eGFR using all 5 equations were greater (or
less negative) with abacavir/lamivudine compared with tenofo-
vir/emtricitabine and were also greater (or less negative) with
efavirenz than with atazanavir/ritonavir (see Supplementary
Table 1). Of note, 2 participants developed a creatinine clear-
ance <60 mL/min using Cockcroft-Gault, and 3, 2, 1, and 0 par-
ticipants, respectively, developed eGFR <60 mL/min per 1.732
at week 96 with MDRD, 2009 CKD-EPI, 2012 CKD-EPI cysta-
tin C, and 2012 CKD-EPI cystatin C-creatinine.
Effects of Interactions Between Treatment Components, Initial
HIV-1 RNA, and Initial Renal Function
Signiﬁcant interactions were found for change in eGFR from
baseline to week 96 between NRTI treatment groups and the
NNRTI/PI treatment groups with Cockcroft-Gault, MDRD,
and the 2009 CKD-EPI equations, but not with the two 2012
CKD-EPI equations (see Supplementary Table 1 and Figures 2
and 3). In particular, tenofovir/emtricitabine with atazanavir/
ritonavir had signiﬁcantly worse eGFR changes compared with
tenofovir/emtricitabine with efavirenz. Signiﬁcant treatment in-
teractions between treatment group and initial HIV-1 RNA
strata were only found for efavirenz vs atazanavir/ritonavir
using 2009 CKD-EPI and 2012 CKD-EPI cystatin C-creatinine;
in particular, atazanavir/ritonavir was associated with worse
changes in eGFR compared with efavirenz within the
<100 000 copies/mL stratum but not the ≥100 000 copies/mL
stratum. There were no signiﬁcant 3-way interactions between
the NRTI treatment components, the NNRTI/PI component,
and initial HIV-1 RNA strata (data not shown).
There were no signiﬁcant interactions between either the
NRTI components or the NNRTI/PI components and initial
renal function strata using any of the 5 renal function equations.
In general, combined across arms, those within the lower initial
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renal function stratum of <90 mL/min (for creatinine clearance)
or <90 mL/min per 1.732 (for eGFR) had signiﬁcantly greater
improvements (or less declines) in renal function (mean [95%
CI]) compared with those in the higher initial renal function
stratum using MDRD (3.0 [−0.7, 6.8] vs −8.4 [−11.0, −5.7]),
2009 CKD-EPI (2.3 [−1.4, 6.0] vs −6.3 [−8.2, −4.3]), 2012
CKD-EPI cystatin C (26.1 [22.7, 29.5] vs 6.5 [4.2, 8.8]), and
2012 CKD-EPI cystatin C-creatinine (14.1 [10.5, 17.7] vs 3.3
[1.3, 5.2]) (all P < .001); the improvements in the lower renal
function stratum were nonsigniﬁcantly greater than those in
the higher stratum using Cockcroft-Gault (6.3 [−0.5, 13.0] vs
1.0 [−1.9, 3.9]; P = .16).
Associations Between Baseline Factors and Changes in Renal
Function At Week 96
We performed multivariable regression models adjusted for
treatment components to evaluate the associations of baseline
factors with renal function change at week 96 using the 3
CKD-EPI equations (Table 2). Assignment to abacavir/
lamivudine vs tenofovir/emtricitabine was variably associated
with 96-week changes in renal function, whereas assignment
to atazanavir/ritonavir remained independently associated
with worse renal function change compared with efavirenz in
these multivariable models. However, other baseline factors (in-
cluding race/ethnicity, initial HIV-1 RNA level, initial presence
Table 1. Baseline Characteristics of the 269 A5224s Study Participantsa,b
Efavirenz Atazanavir/Ritonavir
Total (n = 269)Baseline Characteristic
Tenofovir/
emtricitabine
(n = 69)
Abacavir/
lamivudine
(n = 70)
Tenofovir/
emtricitabine
(n = 65)
Abacavir/
lamivudine
(n = 65)
Age, y 39 (10) 39 (10) 38 (10) 37 (10) 38 (10)
Men, n (%) 58 (84) 56 (80) 56 (86) 59 (91) 229 (85)
Race or ethnicity, n (%)
Black, non-Hispanic 22 (32) 20 (29) 21 (32) 27 (42) 90 (33)
White, non-Hispanic 37 (54) 34 (49) 26 (40) 29 (45) 126 (47)
Hispanic 8 (12) 14 (20) 14 (22) 8 (12) 44 (16)
Other 2 (2) 2 (2) 4 (6) 1 (1) 9 (4)
Body mass index, kg/m2 24.7 (4.0) 25.5 (4.6) 26.2 (5.4) 25.7 (4.5) 25.5 (4.7)
CD4 cell count/µL 248 (160) 231 (167) 226 (142) 238 (189) 236 (165)
HIV-1 RNA level,b log10 copies/mL 4.6 (0.7) 4.6 (0.6) 4.6 (0.7) 4.7 (0.7) 4.6 (0.7)
<100 000 copies/mL, n (%) 56 (81) 59 (84) 52 (80) 48 (74) 215 (80)
≥100 000 copies/mL, n (%) 13 (19) 11 (16) 13 (20) 17 (26) 54 (20)
Hepatitis B surface antigen positive, n (%) 5 (7) 3 (4) 0 (0) 1 (2) 9 (3)
Hepatitis C antibody positive, n (%) 5 (7) 8 (11) 3 (5) 7 (11) 23 (9)
Systolic blood pressure, mm Hg 119 (15) 122 (14) 121 (10) 120 (13) 121 (13)
Diastolic blood pressure, mm Hg 75 (9) 77 (10) 75 (7) 75 (11) 76 (9)
HOMA-IR 1.2 (1.7) 1.6 (1.5) 1.5 (2.1) 1.4 (1.4) 1.4 (1.7)
Creatinine clearance using Cockcroft-Gault, mL/min 118.3(24.5) 122.2 (35.3) 124.0 (35.4) 124.0 (33.0) 122.1 (32.2)
<90 mL/min, n (%) 8 (12) 15 (22) 12 (19) 8 (13) 43 (16)
eGFR using MDRD, mL/min per 1.732 100.6 (18.4) 100.0 (23.6) 100.0 (25.8) 103.0 (20.3) 100.9 (22.0)
<90 mL/min per 1.732, n (%) 21 (31) 25 (37) 24 (39) 16 (25) 86 (33)
eGFR using 2009 CKD-EPI, mL/min per 1.732 107.1 (15.1) 105.7 (19.4) 106.3 (20.5) 109.3 (16.6) 107.1 (17.9)
<90 mL/min per 1.732, n (%) 10 (15) 17 (25) 16 (26) 9 (14) 53 (20)
eGFR using 2012 CKD-EPI CysC, mL/min per 1.732 101.8 (19.2) 95.0 (19.7) 99.5 (21.1) 101.4 (20.6) 99.4 (20.2)
<90 mL/min per 1.732, n (%) 18 (26) 27 (40) 20 (32) 17 (27) 82 (31)
eGFR using 2012 CKD-EPI CysC-Cr, mL/min per 1.732 104.8 (15.6) 99.7 (17.0) 102.9 (19.2) 105.3 (17.0) 103.2 (17.2)
<90 mL/min per 1.732, n (%) 11 (16) 17 (25) 15 (24) 13 (20) 56 (21)
Urine dipstick proteinuria,c n (%) 16 (24) 22 (31) 20 (33) 17 (27) 75 (29)
Abbreviations: CKD-EPI, Chronic Kidney Diseases Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C; eGFR, estimated glomerular filtration rate; HIV,
human immunodeficiency virus; HOMA-IR, homeostasis model assessment-insulin resistance; MDRD, Modification of Diet in Renal Diseases.
a All data presented as mean (standard deviation) or as number (percent). Numbers of missing data for the renal function estimates and for urine dipstick proteinuria
were <10 each for the entire study population.
b HIV-1 RNA strata defined as either <100 000 vs ≥ 100 000 copies/mL at screening.
c Urine dipstick proteinuria defined as any result that was nonnegative.
4 • OFID • Gupta et al
 at R
uth Lilly M
edical Library on M
arch 18, 2016
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
Figure 1. Renal function estimates (mean [95% conﬁdence interval]) by treatment assignment over time using each of the 5 estimating formula.
A, Estimated creatinine clearance using the Cockcroft-Gault equation. B, Estimated glomerular ﬁltration rate (eGFR) using the Modiﬁcation of Diet in
Renal Disease (MDRD) equation. C, eGFR using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. D, eGFR using the
2012 CKD-EPI cystatin C (CysC) equation. E, eGFR using the 2012 CKD-EPI cystatin C-creatinine (CysC-Cr) equation. Abbeviations: ABC/3TC, abacavir/lam-
ivudine; ATV/rtv, atazanavir/ritonavir; EFV, efavirenz; TDF/FTC, tenofovir/emtricitabine.
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Figure 2. Changes in renal function estimates (mean [95% conﬁdence interval]) by nucleoside reverse-transcriptase treatment component. No signiﬁcant
interactions were noted between nucleoside reverse-transcriptase inhibitor (NRTI) and non-NRTI (NNRTI)/protease inhibitor (PI) treatment components using
the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation (A) or the 2012 CKD-EPI cystatin C-creatinine equation (B). Thus,
we pooled the NRTI groups in the ﬁgure panels for these 2 equations. However, because treatment interactions were noted using the Cockcroft-Gault
equation (C), Modiﬁcation of Diet in Renal Disease (MDRD) equation (D), and the 2009 CKD-EPI equation (E), the changes in renal function when the
NRTI components are combined with either an NNRTI or PI are shown separately to highlight these differences. *P value for 2-sample t test;
**P value for linear regression model adjusting for the other treatment component and the component interaction. Abbreviations: ABC/3TC, abacavir/
lamivudine; ATV/rtv, atazanavir/ritonavir; Cr, creatinine; CysC, cystatin C; EFV, efavirenz; TDF/FTC, tenofovir/emtricitabine.
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Figure 3. Changes in renal function estimates [mean (95% conﬁdence interval)] by nonnucleoside reverse-transcriptase inhibitor (NNRTI) vs protease
inhibitor (PI) component. No signiﬁcant interactions were noted between NRTI and NNRTI/PI treatment components using the 2012 Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) cystatin C equation (A) or the 2012 CKD-EPI cystatin C-creatinine equation (B). Thus, we pooled the NNRTI/PI groups in
the ﬁgure panels for these 2 equations. However, because treatment interactions were noted using the Cockcroft-Gault equation (C), Modiﬁcation of Diet in
Renal Disease (MDRD) equation (D), and the 2009 CKD-EPI equation (E), the changes in renal function when the NNRTI/PI components are combined with
each of the 2 NRTI components are shown separately to highlight these differences. *P value for 2-sample t test; **P value for linear regression model
adjusting for the other treatment component and the component interaction. ABC/3TC, abacavir/lamivudine; ATV/rtv, atazanavir/ritonavir; Cr, creatinine;
CysC, cystatin C; EFV, efavirenz; TDF/FTC, tenofovir/emtricitabine.
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of urine dipstick proteinuria, and initial systolic blood pressure)
were variably associated with week 96 renal function change de-
pending on which CKD-EPI renal function estimating equation
was used.
DISCUSSION
Because currently recommended antiretroviral regimens for ini-
tial treatment have become similarly and consistently efﬁcacious
in controlling viral replication, treatment-associated complica-
tions, including nephrotoxicities, have become increasingly im-
portant in choosing therapy. To our knowledge, this is the ﬁrst
study utilizing the 2012 cystatin C-based GFR estimating for-
mulae in determining the changes in renal function with initi-
ation of ART in patients infected with HIV. As such, we have
shown that the changes in eGFR associated with initiation of
these regimens, and, in turn, the interpretations of their neph-
rotoxicity proﬁles depend greatly on which renal function esti-
mating equation is used.
Our results conﬁrm those from other studies that have found
worse changes in eGFR with the initiation of tenofovir com-
pared with other NRTIs, especially in those receiving concom-
itant PIs [4, 6–8], although not all studies have found poorer
renal function changes with tenofovir compared with abacavir
in randomized trials [9, 11, 30]. The parent trial of this renal
substudy, ACTG 5202, found a signiﬁcant relative decline in es-
timated creatinine clearance as estimated by Cockcroft-Gault
with tenofovir/emtricitabine in combination with atazanavir/ri-
tonavir compared with its combination with efavirenz [13]. We
found similar differences in the A5224s substudy when using
the 2009 CKD-EPI and 2012 CKD-EPI cystatin C-creatinine
equations, although we did not ﬁnd signiﬁcant differences
when using the 2012 CKD-EPI cystatin C equation. We also
noted signiﬁcant interactions between the nucleoside compo-
nents and the third treatment component (efavirenz vs
atazanavir/ritonavir) with Cockcroft-Gault, MDRD, and 2009
CKD-EPI, but not with either of the two 2012 equations incor-
porating cystatin C. In particular, the 96-week mean (95% CI)
renal function changes for tenofovir/emtricitabine combined
with atazanavir/ritonavir widely ranged from −14.9 (−19.7,
−10.1) mL/min per 1.732 with MDRD to +8.9 (+4.2, +13.7)
mL/min per 1.732 with 2012 CKD-EPI cystatin C. The ranges
of renal function changes within the other treatment arms
were similarly varied. Thus, the choice of renal function equa-
tion may indeed inﬂuence our understanding of the relative
renal safety proﬁles of these antiretroviral regimens.
The mechanism by which tenofovir with PIs may lead to
renal toxicity has been presumed to be due to accumulation
of tenofovir in renal proximal tubule cells secondary to inhibi-
tion of efﬂux transporters by PIs, especially in genetically
Table 2. Multivariable Models of the Effects of Baseline Factors on Change in Renal Function at 96 Weeks With the 3 CKD-EPI Estimating
Equationsa
2009 CKD-EPI 2012 CKD-EPI CysC 2012 CKD-EPI CysC-Cr
Baseline Factor
Estimated mean
change (95% CI) P value
Estimated mean
change (95% CI) P value
Estimated mean
change (95% CI) P value
ATV/rtv (vs EFV) −11.7 (−16.7, −6.6) <.001 −6.3 (−10.7, −1.8) .006 −8.0 (−11.6, −4.4) <.001
ABC/3TC (vs TDF/FTC) 0.9 (−4.0, 5.8) .70 4.3 (−0.1, 8.7) .058 4.9 (1.3, 8.5) .008
ABC/3TC*ATV/rtv interaction
(vs not ABC/3TC and ATV/rtv)
7.5 (0.4, 14.6) .039
Race/ethnicity
Non-Hispanic Black vs
non-Hispanic White
−3.4 (−8.5, 1.6) .047
Hispanic (any race) vs
non-Hispanic White
−7.8 (−14.2, −1.4)
HIV-1 RNA (per 1 log10
copies/mL higher)
5.8 (2.5, 9.2) .001 3.3 (0.6, 6.0) .017
Negative urine dipstick protein
(vs nonnegative urine
dipstick protein)
−6.9 (−12.0, −1.8) .008
Systolic blood pressure (per
10 mmHg higher)
−2.0 (−3.7, −0.3) .025
Abbreviations: ABC, abacavir; ATV/rtv, atazanavir/ritonavir; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Cr, creatinine; CysC, cystatin C; EFV,
efavirenz; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model assessment-insulin resistance; 3TC, lamivudine; TDF, tenofovir.
a Results are presented after adjustment for treatment components, and only variables with significant associations using at least 1 CKD estimating equation are
shown in the table. Other variables assessed in the models but not found to be statistically significantly associatedwith week 96 renal function changewith any CKD
estimating equation include the following: age, male vs female, body mass index, HIV-1 RNA stratum (<100 000 vs ≥100 000 copies/mL), CD4 cell count, diastolic
blood pressure, hepatitis B or C coinfections, HOMA-IR, and weight.
b All renal function data in units of mL/min per 1.732.
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predisposed individuals [31, 32], although this has not been
conﬁrmed in all studies [33].
Atazanavir/ritonavir has also been recently linked with
chronic kidney disease [14, 15], which has been speculated to
be due to intrarenal crystallization of atazanavir with associated
interstitial nephritis [34, 35].The current study does indeed sug-
gest that use of atazanavir/ritonavir is associated with worse
renal function changes compared with efavirenz using any of
the 5 estimating equations. As demonstrated in vitro, ritonavir
may potentially increase serum creatinine concentrations via in-
hibition of creatinine efﬂux through the multidrug and toxin
extrusion 1 (MATE1) transporter in the proximal tubule cell
[36]. However, our data do not appear to be solely due to any
potentially isolated effect of MATE1 inhibition by ritonavir.
Using the 2012 CKD-EPI cystatin C equation (which does not
include creatinine), eGFR increased in all groups, but there were
still lower improvements in those assigned to abacavir/lamivu-
dine with atazanavir/ritonavir compared with those assigned to
abacavir/lamivudine with efavirenz (10.7 vs 18.0 mL/min per
1.732) and in those assigned to tenofovir/emtricitabine with ata-
zanavir/ritonavir compared with those assigned to tenofovir/
emtricitabine with efavirenz (8.9 vs 12.7 mL/min per 1.732)
(see Supplementary Table 1). As shown in Figure 3A, we see
that there remains a signiﬁcant difference between eGFR chang-
es using the 2012 CKD-EPI cystatin C equation when pooling
the NRTI components. The differences in eGFR between ataza-
navir/ritonavir and efavirenz using an equation not incorporat-
ing serum creatinine are of similar magnitude to those when
using creatinine-based equations. As such, atazanavir/ritonavir
likely has an effect on eGFR independent of any possible serum
creatinine increase due simply to MATE1 inhibition.
Interactions between the atazanavir/ritonavir or efavirenz
components with the nucleoside treatment component were
found, however, with the 3 equations incorporating only creat-
inine and not with those including cystatin C. In addition, sig-
niﬁcantly less beneﬁcial changes in eGFR with atazanavir/
ritonavir were found in those whose screening HIV-1 RNA lev-
els were <100 000 copies/mL. It is possible that the potential ad-
verse renal toxicity of atazanavir/ritonavir is unmasked in the
lower viral load stratum because this group is less likely to ben-
eﬁt from improvements in renal function due to reduction in
initial viremia, as might be expected in the higher stratum [37].
The key new ﬁnding in this study is that the apparent differ-
ences in renal function within treatment groups are highly de-
pendent on the eGFR estimating equation used. No previous
studies have used cystatin C-based estimating equations to as-
sess the effects of antiretroviral initiation on renal function. A
recent evaluation by Inker et al [23] in HIV-infected patients re-
ceiving virologically suppressive antiretroviral treatment sug-
gested that the 2012 CKD-EPI equation incorporating both
cystatin C and creatinine was marginally more accurate for es-
timating GFR than the 2012 CKD-EPI equation using only
cystatin C and the 2009 CKD-EPI equation using only creati-
nine compared with iohexol clearance as the reference standard.
Inker et al [21] has previously suggested that the greater accura-
cy of the 2012 CKD-EPI cystatin C-creatinine equation may be
due to reduced variances of postulated non-GFR determinants
of these 2 renal markers, such as inﬂammation, when used to-
gether as opposed to using each alone. Gagneux-Brunon et al
[25]performed a similar study in an HIV-infected European co-
hort, which had appreciably different demographic characteris-
tics than the one studied by Inker et al [21], and did not ﬁnd
signiﬁcant differences amongst the 3 CKD-EPI equations. How-
ever, both studies demonstrated that the MDRD equation was
signiﬁcantly less accurate than any of the CKD-EPI equations.
It should be noted that these newer equations have not been val-
idated against direct GFR measurement methods in HIV-
infected, treatment-naive patients. As such, the improvements
in renal function, especially those found in the ﬁrst 24 weeks
(as shown in Figures 2 and 3), with the cystatin C-based equa-
tions may not only reﬂect true improvements in GFR but might
also be inﬂuenced by reductions in inﬂammation and viremia
or by improvements in CD4 cell counts, all of which have
been variably associated with cystatin C levels [38]. In fact,
the recent study by Bhasin et al [24] suggests that the 2012
CKD-EPI cystatin C equation, but not the other 2 CKD-EPI
equations, was biased against true GFR measurement by greater
T cell activation, higher HIV-1 RNA levels, and use of ART.
Using the 2012 CKD-EPI cystatin C-creatinine equation, we
consider that treatment with tenofovir/emtricitabine with ataza-
navir/ritonavir has no noticeable effect on renal function at 96
weeks (mean change −1.2 [95% CI, −5.1, 2.6] mL/min per
1.732) and that treatment with the other once-daily regimens
in this study would lead to improved renal function. On the
other hand, using either the MDRD equation or the 2009
CKD-EPI equation, we conclude that there are signiﬁcant de-
clines from baseline in eGFR with tenofovir/emtricitabine com-
bined with atazanavir/ritonavir with essentially neutral effects
with the other 3 treatment arms. It is plausible to ﬁnd that
renal function generally improves with any ART given the
known detrimental effects of untreated HIV on renal function,
even in those without classic risk factors for HIV-associated ne-
phropathy such as patients of black race [37]. Indeed, we found
that the improvements in renal function were better in those
with initial eGFR lower than 90 mL/min per 1.732, which sup-
ports the concept that untreated HIV does indeed have negative
effects on renal function. Thus, the neutral changes found with
tenofovir/emtricitabine using the 2012 CKD-EPI cystatin C-
creatinine equation may be due to opposing effects of toxicity
from this particular regimen and the beneﬁts of virologic
suppression.
Recent evidence suggests that the 2012 CKD-EPI cystatin
C-creatinine equation is the most accurately available method
to identify patients, including those with HIV infection, with
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reduced renal function who have the highest risk of long-term
adverse outcomes [18, 20]. Since our data suggest that eGFR
using the 2012 CKD-EPI combined equation improves at 96
weeks with use of tenofovir/emtricitabine with efavirenz, abaca-
vir/lamivudine with efavirenz, or abacavir/lamivudine with ata-
zanavir/ritonavir, then long-term outcomes may improve in
those receiving any of these three regimens. However, eGFR
using the 2012 CKD-EPI combined equation did not change
at 96 weeks with use of tenofovir/emtricitabine with atazana-
vir/ritonavir; this may suggest that the contribution of renal
function to long-term outcomes may not be impacted (either
positively or negatively) with the use of this particular regimen.
However, additional research is needed to determine whether
using the 2012 CKD-EPI cystatin C-creatinine equation for rou-
tine clinical monitoring of renal function in those receiving
ART actually leads to changes in management that would pre-
vent future complications in those with reduced renal function.
It should be noted that, regardless of the estimating equation
used, the development of eGFR <60 mL/min per 1.732 at 96
weeks was infrequent in this trial.
We also developed 3 different multivariable models to identify
baseline factors associated with 96-week renal function changes
using the 3 CKD-EPI equations. We found that the baseline fac-
tors assessed were variably associated with changes in eGFR de-
pending on the equation used. These results again suggest that
the choice of eGFR estimating equation directly impacts our un-
derstanding of which factors are responsible for changes in renal
function in HIV-infected patients initiating treatment.
The limitations of this study should be acknowledged. We did
not directly measure renal function to validate and identify the
most accurate estimating equation for these patients initiating
antiretrovirals. Although our study is one of the longest to as-
sess changes in renal function with initiation of ART, we cannot
make any conclusions regarding differences between regimens
beyond 96 weeks. Our results may not be generalizable to pa-
tients with pretreatment creatinine clearance <60 mL/min or
to those with diabetes, groups that were excluded from this sub-
study. Although we measured cystatin C centrally, we did not do
so for creatinine. We also acknowledge that neither creatinine
nor cystatin C were calibrated against international standards,
which may lead to analytical drift of the measurements [39].
However, because we assessed changes in renal function, the po-
tential variability of these results due to the lack of either cen-
tralized or standardized measurement is somewhat minimized.
Another limitation was the lack of blinding for the efavirenz and
atazanavir/ritonavir treatment components, although the
nucleoside treatment components were blinded. Finally, these
analyses were performed without adjustment for multiple com-
parisons, thereby increasing the possibility of type I errors for
falsely detecting differences.
In summary, we found that initiation of ART with tenofovir/
emtricitabine and atazanavir/ritonavir led to less beneﬁcial
changes in eGFR at 96 weeks compared with abacavir/lamivu-
dine and efavirenz, respectively. However, the magnitudes, di-
rections, and statistical signiﬁcances of these changes in renal
function varied with the estimating equation used. If the
newer cystatin C-based equations are indeed conﬁrmed to be
more clinically useful, then the renal proﬁles of antiretroviral
regimens should be reinterpreted and, as such, would have im-
portant implications for HIV clinical care.
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